|
|
|
|
|||||
|
|
|
GE HealthCare Technologies Inc. GEHC recently introduced SIGNA Sprint, a next-generation ultra-premium 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025, engineered to push the boundaries of traditional MRI performance. With a 65/200 per-axis gradient strength and built-in AI tools, SIGNA Sprint delivers sharp imaging for cardiology and oncology, enabling faster, more accurate diagnostics.
As healthcare providers increasingly prioritize imaging solutions that balance diagnostic power, cost-effectiveness and patient comfort, SIGNA Sprint stands out with its blend of cutting-edge performance and accessibility. Built-in AI technologies streamline workflows while its patient-centric design, including free-breathing capability and AIR Coils, enhances the overall imaging experience. With SIGNA Sprint, GE HealthCare aims to redefine what's possible at 1.5T, expanding clinical capabilities without the added infrastructure demands of higher-field MRI systems.
Shares of the company moved north 6.1% and closed at $74.11 on Monday following the announcement, primarily due to the U.S.-China trade deal. In the year-to-date period, GEHC shares have lost 5.3% against the industry’s 5.3% growth. The S&P 500 decreased 4.5% in the same time frame.
The launch of SIGNA Sprint positions GE HealthCare to strengthen its premium MRI market presence with a cost-effective, high-performance alternative to 3.0T systems. Its AI-driven capabilities and enhanced diagnostic features make it appealing to hospitals and research institutions, driving adoption and recurring service revenue. This innovation could support sustained revenue growth, improve investor confidence, and enhance long-term stock performance.
Meanwhile, GEHC currently has a market capitalization of $31.99 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%.
SIGNA Sprint is an ultra-premium, wide-bore MRI system designed to deliver imaging power typically found in 3.0T systems on the more accessible 1.5T platform. A FDA 510(k) application is pending for the system, and clearance is expected to expand GEHC’s diagnostic capabilities in cardiology, oncology, and other advanced clinical and research domains. It delivers exceptional diffusion imaging, vital for oncology, and enables crystal-clear visualization of sub-millimetric structures critical in precision care.
SIGNA Sprint’s core advantage lies in its integrated AI technologies, AIR Recon DL, Sonic DL, and AIR x, which enhance image reconstruction, accelerate scan times, and improve diagnostic accuracy. These deep learning tools enable quantitative MRI, offering deeper insights into tissue characteristics, particularly in cardiac imaging, while streamlining workflows and enhancing treatment monitoring. Designed for patient comfort with a 70cm wide bore, free-breathing capabilities, and AIR Coils, SIGNA Sprint combines advanced imaging power with improved patient experience. As demand for scalable MRI solutions rises, particularly in cardiology and oncology, SIGNA Sprint offers a cost-effective, AI-powered system poised to drive both clinical impact and commercial success for GE HealthCare.
At ISMRM 2025, GE HealthCare is expected to showcase its latest MRI innovations, including SIGNA Sprint, which features SIGNA MAGNUS— a high-resolution head-only scanner with advanced gradients. Additionally, Sonic DL 3D, a deep learning-based MRI acceleration technology, and Freelium, a helium-free sealed magnet platform in development to reduce helium reliance, are also expected to be showcased. These advancements highlight GE HealthCare's leadership in MRI technology.
In recent months, GEHC has made strategic moves to expand its imaging services and AI capabilities. In March, GEHC unveiled Freelium, a next-generation sealed magnet platform at ECR 2025, designed to revolutionize Magnetic Resonance imaging. The platform uses less than 1% of helium compared to traditional systems, promoting sustainability and expanding access to quality imaging in helium-scarce regions. In January, GEHC partnered with Sutter Health to form a seven-year Care Alliance, enhancing access to innovative imaging services and improving the patient and clinician experience across the Sutter Health network. This collaboration aims to create a more seamless and coordinated healthcare system.
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX.
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 4 hours | |
| 6 hours | |
| 7 hours | |
| 7 hours | |
| 7 hours | |
| 8 hours | |
| 9 hours | |
| May-12 | |
| May-12 | |
| May-12 | |
| May-12 | |
| May-12 | |
| May-12 | |
| May-12 | |
| May-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite